Veraxa Biotech AG Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Lead Candidate VXA-102 IND/CTA Readiness Timeline AnnuallyTarget: Early 2028
Total Pipeline Program Count Quarterly8
Watch Items
- Preclinical safety and efficacy validation of lead BiTAC-TCE candidate VXA-102Trigger: Completion of non-clinical development plan aligned with Paul-Ehrlich-Institute (PEI) Scientific AdviceAction: Initiate IND-enabling studies and cell line development
- Cash runway and capital burn rate post-SPAC mergerTrigger: Cash balance falling below $15 millionAction: Utilize the $50 million share purchase agreement or secure strategic pharmaceutical partnerships
Research as of 24 Jul 2026